Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.41 |
| ▸ | GLRB | P48167 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18237754 | 0.86 | ALDH1A1 (0.62) | ALDH1A1MAPK1PKMSMN1; SMN2KDM4E | |
| SCHEMBL18227257 | 0.80 | ALDH1A1 (0.54) | ALDH1A1MAPK1PKMSMN1; SMN2KDM4E | |
| SCHEMBL18237352 | 0.74 | KMT2A (0.40) | ALDH1A1MAPK1SMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL10312338 | 0.74 | ALDH1A1 (0.68) | ALDH1A1MAPK1PKMSMN1; SMN2KDM4E | |
| SCHEMBL18227206 | 0.71 | ALDH1A1 (0.64) | ALDH1A1MAPK1PKMSMN1; SMN2KDM4E | |
| SCHEMBL18237454 | 0.71 | SMN1; SMN2 (0.37) | ALDH1A1MAPK1PKMSMN1; SMN2KMT2A | |
| SCHEMBL14150232 | 0.71 | ALDH1A1 (0.58) | ALDH1A1MAPK1PKMSMN1; SMN2KDM4E | |
| SCHEMBL14150586 | 0.70 | MAPK1 (0.65) | ALDH1A1MAPK1PKMSMN1; SMN2KDM4E | |
| SCHEMBL10453840 | 0.68 | ALDH1A1 (0.96) | ALDH1A1MAPK1PKMSMN1; SMN2KDM4E | |
| SCHEMBL19755165 | 0.68 | ALDH1A1 (0.68) | ALDH1A1MAPK1PKMSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-11291731-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2019-09-26 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | ALDH1A1 2151/4885MAPK1 4565/4885PKM 413/4885 |
| US-11291731-B2 | Silicon based drug conjugates and methods of using same | CD44, MSN, AS3MT | ALDH1A1 2151/4885MAPK1 4565/4885PKM 413/4885 |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | ALDH1A1 2151/4885MAPK1 4565/4885PKM 413/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | ALDH1A1 2151/4885MAPK1 4565/4885PKM 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.